400 related articles for article (PubMed ID: 10634339)
1. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
Havlir DV; Hellmann NS; Petropoulos CJ; Whitcomb JM; Collier AC; Hirsch MS; Tebas P; Sommadossi JP; Richman DD
JAMA; 2000 Jan; 283(2):229-34. PubMed ID: 10634339
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Descamps D; Flandre P; Calvez V; Peytavin G; Meiffredy V; Collin G; Delaugerre C; Robert-Delmas S; Bazin B; Aboulker JP; Pialoux G; Raffi F; Brun-Vézinet F
JAMA; 2000 Jan; 283(2):205-11. PubMed ID: 10634336
[TBL] [Abstract][Full Text] [Related]
3. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
4. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
9. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
[TBL] [Abstract][Full Text] [Related]
11. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Descamps D; Flandre P; Joly V; Meiffrédy V; Peytavin G; Izopet J; Tamalet C; Zeng AF; Harel M; Lastère S; Aboulker JP; Yéni P; Brun-Vézinet F;
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):464-71. PubMed ID: 12473833
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.
Wintergerst U; Hoffmann F; Sölder B; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH
Pediatr Infect Dis J; 1998 Jun; 17(6):495-9. PubMed ID: 9655541
[TBL] [Abstract][Full Text] [Related]
13. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
14. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
15. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
17. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
18. Final analysis of the Trilège induction-maintenance trial: results at 18 months.
Flandre P; Raffi F; Descamps D; Calvez V; Peytavin G; Meiffredy V; Harel M; Hazebrouck S; Pialoux G; Aboulker JP; Brun Vezinet F
AIDS; 2002 Mar; 16(4):561-8. PubMed ID: 11872999
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
Neumann AU; Tubiana R; Calvez V; Robert C; Li TS; Agut H; Autran B; Katlama C
AIDS; 1999 Apr; 13(6):677-83. PubMed ID: 10397562
[TBL] [Abstract][Full Text] [Related]
20. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
